SEARCH RESULTS FOR:

Mining
United States

Tom Meuzelaar

FOUNDER AND OWNER, LIFE CYCLE GEO
"Machine learning can aid significantly in the identification of various water types which supports management strategies such as monitoring potential impacts across project boundaries. It is an indispensable tool in supporting ongoing measurement of water quality throughout the life cycle."
Petrochemicals & Chemicals
Argentina

Florencia Rodríguez

EXECUTIVE BUSINESS MANAGER, YPF QUÍMICA
"The 4x4 Plan is an ambitious strategy to quadruple YPF's production and value in four years."
Petrochemicals & Chemicals
Brazil

Carlos De Lion Neto

SOUTHERN CONE PRESIDENT, ARKEMA
"As the scale of sustainable products increases, it becomes easier to introduce these materials into both mature markets and developing markets."
Mining
Chile

Ben Pullinger and Craig Nelsen

PRESIDENT AND CEO (BP) AND CHAIRMAN (CN), ATEX RESOURCES
"If we consider current trends, such as shortened permitting timelines and national infrastructure investments, the future looks promising."
Mining
Chile

Iván Arriagada

CEO, ANTOFAGASTA MINERALS
"The next stage of our growth story has begun. In Q1 2024, we started the construction of the Centinela Second Concentrator Project, which will add a further 170,000 t/y of copper-equivalent production."
Mining
Chile

Mining, Water and Climate Change

Chile Mining 2024 - Digital Interactive
Desalination and recirculation preserve Chile’s scarcest resource
Mining
Peru

Test CS v2

WORK TITLE
Test CS v2 for Walsh
Mining
Peru

Test CS v3

WORK TITLE
Test CS v3 for Walsh
Mining
Peru

Erika Gabriel

GENERAL MANAGER, BIZALAB
"Although we are smaller than a multinational company, our mineralogy specialization gives us a distinctive advantage in the market."
Mining
Peru

Test CS

WORK TITLE
Test CS for Walsh

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL